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Abstract
Objective This study aimed at evaluating the cost-effec-
tiveness of human papillomavirus virus (HPV) vaccination
in France, using a generally applicable succinct cohort
model.
Methods A lifetime Markov cohort model, adapted to the
French setting, simulate the natural history of oncogenic
HPV infection towards cervical cancer (CC). Additional
modules account for the effects of screening and vaccina-
tion. The girls’ cohort is vaccinated at age 12 and follows
current screening. Costs and outcomes (discounted at 3 and
1.5%, respectively) were compared with a cohort receiving
screening alone.
Results The model results agreed well with real-life data.
Vaccination in addition to screening would substantially
reduce the incidence of and mortality from CC, compared
with screening alone, at an estimated cost-effectiveness of
€9,706 per quality-adjusted-life-year. Sensitivity analysis
showed that the discount rate and the parameters related to
the disease history have the largest impact on the results.
Conclusion This succinct cohort model indicated that
HPV vaccination would be a cost-effective policy option in
France. It uses readily available data and should be gen-
erally applicable to the evaluation of HPV vaccination in a
variety of countries and settings.
Keywords Vaccination  Human papillomavirus 
Cervical cancer  Cost-effectiveness
Introduction
Cervical cancerrepresentsasubstantialdiseaseburden,with
an estimated 530,000 new cases and 275,000 deaths each
year worldwide (Ferlay et al. 2010). Screening techniques
such as cytology and testing for human papillomavirus
(HPV) infection are available and vaccination against HPV
now offers a promising additional strategy for management
of cervical cancer.
HPV infection is closely associated with cervical cancer
(zur Hausen 1996; Walboomers et al. 1999; Bosch et al.
2002). One hundred and twenty types of HPV have been
identiﬁed (Trottier and Franco 2006), classiﬁed into high-
risk (oncogenic) types that can lead to pre cervical cancer
lesions [low-grade intraepithelial neoplasia (CIN) lesions
(CIN 1) and high-grade CIN (CIN2/3)] and cervical cancer
and low-risk (non-oncogenic) types that can produce gen-
ital warts or CIN 1 but not CIN 2/3 nor cervical cancer
(Munoz et al. 2006). Two oncogenic HPV types, HPV-16
and HPV-18, are responsible for 70% of detected cervical
cancer cases worldwide (WHO/ICO 2010). Clinical studies
have shown that the currently available bivalent vaccine
targeting HPV 16/18 is effective against these types but
also even beyond these and well tolerated in preventing
infections and cervical intraepithelial neoplasia (CIN)
(Harper et al. 2006; Paavonen et al. 2009). Addition of
HPV vaccination at an early age (12 years) to screening
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123offers a potentially cost-effective method of reducing cer-
vical cancer incidence (Kim et al. 2008; Marra et al. 2009).
Astheclinicalbeneﬁtsofvaccinationaccrueinthefuture,
long-term clinical data will take some decades to collect. In
the meantime, modelling studies can integrate currently
availableclinicaldatawithcountry-speciﬁcepidemiological
data to evaluate the potential long-term impact of adding
vaccination to screening. Models can also test different
scenariostoinvestigatetheeffectofuncertaintyaroundsome
of the input parameters. Several models of HPV vaccination
havebeenpublished,withvaryingdegreesofcomplexityand
transparency (Kim et al. 2008). In general, sophisticated
modelsleadtomoreaccurateresultsbutarelikelytobemore
difﬁcult to understand. Moreover,detailed input data are not
available for all countries, and simpler models may be more
widely applicable (Debicki et al. 2008). We developed a
succinct model, based on an existing model (Goldie et al.
2004) and close to the one developed by Kulsingam and
Myers (2003) that allows transparent estimation of the cost-
effectiveness of HPV vaccination using a data set that is
easilyaccessibleformostcountries.Itcanbeusedtoprovide
a rapid preliminary assessment of various vaccination and
screening scenarios, such as vaccination with or without
screening (opportunistic or organised), at various ages and
with or without catch-up vaccination. The model has been
described in detail and its performance compared with a
morecomplexmodellingapproachelsewhere(Debickietal.
2008). In the present paper we describe its application to
evaluating the cost-effectiveness of HPV vaccination in a
speciﬁc country, France.
Methods
Model design
The model is a lifetime Markov cohort model developed in
Microsoft Excel, based on a previously published model
(Debicki et al. 2008) with some simpliﬁcations to facilitate
its transposition to different settings (Debicki et al. 2008).
The model consists of three modules.
• Natural history, with nine health states (no HPV,
oncogenic HPV, CIN stage 1, CIN stage 2/3, persistent
CIN stage 2/3, cervical cancer, cancer cured, cervical
cancer death, death from other cause)
• Screening, with two additional health states (detected
CIN stage 1, detected CIN stage 2/3)
• Vaccination, which alters the transition probability for
moving from the ‘no HPV’ health state to the ‘onco-
genic HPV’ health state, based on vaccine efﬁcacy data
The screening module allows the modelling of different
screening patterns, such as opportunistic screening
(irregular) or organised (national program with a ﬁxed
screening interval within a given age range) screening at
different ages and intervals.
The model has a cycle time of 1 year and is run over a
maximum of 96 cycles, representing the lifetime of the
cohort of 11 years girls modelled. The 1-year cycle time
facilitates the use of country speciﬁc available statistical
data most frequently reported on an annual basis.
Each health state has an associated cost and utility score
[between 0 and 1, quality-adjusted life-years (QALY)]. At
the end of the model (96 cycles) the total costs and total
QALYs over each year are summed to estimate lifetime
outcomes (life-years, cervical cancer cases, cervical cancer
deaths, and QALYs) for the cohort.
Input data
The model inputs for the base case are summarised in
Table 1, together with the values used for the univariate
deterministic sensitivity analyses. Input data were obtained
from published literature and/or ofﬁcial reports where
possible, and were further validated by a panel of four
French experts to insure applicability to the French settings
especially for data reported for other countries whenever
no French data were available (Table 1).
Transition probabilities
The probability for the transition from persistent CIN stage
2/3 to cervical cancer was estimated by calibrating the
model to the observed cancer incidence data (see section on
Model calibration and validation). Other transition proba-
bilities were based on published literature, national
statistics, current guidelines and expert opinion (Table 1).
Costs
The costs associated with events in the model were esti-
mated from a limited societal perspective (all direct
healthcare costs) at 2007 values, and are listed in Table 1.
Some of the event costs were based on a treatment algo-
rithm supplied by the experts panel, to which unit costs
were applied. For positive detected CIN lesion, it was
assumed that most treatment costs would fall in the ﬁrst
year, and costs in subsequent years would only consist of
follow-up costs such as more frequent pap smear tests.
Disutility values
A utility value of 1 (no disutility) was assigned to the
following health states: no HPV, oncogenic HPV, CIN 1
and CIN 2/3, as the model assumes that no disutility occurs
from competing illnesses. A utility value of 0 was assigned
154 N. Demarteau et al.
123T
a
b
l
e
1
I
n
p
u
t
d
a
t
a
v
a
l
u
e
s
f
o
r
b
a
s
e
c
a
s
e
a
n
d
s
e
n
s
i
t
i
v
i
t
y
a
n
a
l
y
s
e
s
P
a
r
a
m
e
t
e
r
B
a
s
e
c
a
s
e
v
a
l
u
e
U
n
i
v
a
r
i
a
t
e
s
e
n
s
i
t
i
v
i
t
y
a
n
a
l
y
s
i
s
R
e
f
e
r
e
n
c
e
L
o
w
e
r
U
p
p
e
r
T
r
a
n
s
i
t
i
o
n
p
r
o
b
a
b
i
l
i
t
i
e
s
N
o
H
P
V
t
o
H
P
V
0
–
0
.
1
2
3
2
0
%
l
e
s
s
t
h
a
n
b
a
s
e
c
a
s
e
2
0
%
m
o
r
e
t
h
a
n
b
a
s
e
c
a
s
e
R
i
e
t
h
m
u
l
l
e
r
e
t
a
l
.
(
1
9
9
9
)
,
C
l
a
v
e
l
e
t
a
l
.
(
2
0
0
1
)
,
B
o
u
l
a
n
g
e
r
e
t
a
l
.
(
2
0
0
4
)
,
B
e
b
y
-
D
e
f
a
u
x
e
t
a
l
.
(
2
0
0
4
)
,
D
a
l
s
t
e
i
n
e
t
a
l
.
(
2
0
0
4
)
H
P
V
t
o
N
o
H
P
V
0
.
5
0
N
A
N
A
M
e
l
n
i
k
o
w
e
t
a
l
.
(
1
9
9
8
)
,
N
o
b
b
e
n
h
u
i
s
e
t
a
l
.
(
2
0
0
1
)
,
e
x
p
e
r
t
o
p
i
n
i
o
n
H
P
V
t
o
C
I
N
1
0
.
0
5
N
A
N
A
M
o
s
c
i
c
k
i
e
t
a
l
.
(
2
0
0
1
)
C
I
N
1
c
l
e
a
r
a
n
c
e
0
.
5
0
N
A
N
A
M
e
l
n
i
k
o
w
e
t
a
l
.
(
1
9
9
8
,
N
o
b
b
e
n
h
u
i
s
e
t
a
l
.
(
2
0
0
1
)
,
S
a
n
d
e
r
s
a
n
d
T
a
i
r
a
(
2
0
0
3
)
,
V
a
n
D
e
V
e
l
d
e
e
t
a
l
.
(
2
0
0
7
)
C
I
N
1
t
o
C
I
N
2
/
3
0
.
1
2
N
A
N
A
M
e
l
n
i
k
o
w
e
t
a
l
.
(
1
9
9
8
)
,
S
a
n
d
e
r
s
a
n
d
T
a
i
r
a
(
2
0
0
3
,
V
a
n
D
e
V
e
l
d
e
e
t
a
l
.
(
2
0
0
7
)
C
I
N
2
/
3
c
l
e
a
r
a
n
c
e
0
.
2
7
5
N
A
N
A
(
M
e
l
n
i
k
o
w
e
t
a
l
.
1
9
9
8
)
C
I
N
2
/
3
t
o
p
e
r
s
i
s
t
e
n
t
C
I
N
2
/
3
0
.
1
2
5
N
A
N
A
M
e
l
n
i
k
o
w
e
t
a
l
.
(
1
9
9
8
)
P
e
r
s
i
s
t
e
n
t
C
I
N
2
/
3
t
o
c
e
r
v
i
c
a
l
c
a
n
c
e
r
0
–
0
.
1
0
N
A
N
A
A
s
s
u
m
p
t
i
o
n
b
a
s
e
d
o
n
c
a
l
i
b
r
a
t
i
o
n
t
o
c
e
r
v
i
c
a
l
c
a
n
c
e
r
i
n
c
i
d
e
n
c
e
C
a
n
c
e
r
c
u
r
e
d
0
.
2
0
3
N
A
N
A
C
o
l
e
m
a
n
e
t
a
l
.
(
2
0
0
3
)
A
d
d
i
t
i
o
n
a
l
m
o
r
t
a
l
i
t
y
w
i
t
h
c
e
r
v
i
c
a
l
c
a
n
c
e
r
0
.
0
7
5
N
A
N
A
E
x
b
r
a
y
a
t
(
2
0
0
2
,
C
o
l
e
m
a
n
e
t
a
l
.
(
2
0
0
3
)
,
F
e
r
l
a
y
e
t
a
l
.
(
2
0
0
4
)
D
e
a
t
h
r
a
t
e
s
0
.
0
0
4
–
1
N
A
N
A
I
n
s
t
i
t
u
t
N
a
t
i
o
n
a
l
d
e
s
E
t
u
d
e
s
D
e
´
m
o
g
r
a
p
h
i
q
u
e
s
(
2
0
0
4
)
S
c
r
e
e
n
i
n
g
S
c
r
e
e
n
i
n
g
s
e
n
s
i
t
i
v
i
t
y
0
.
5
8
–
0
.
6
1
0
.
4
6
–
0
.
4
9
0
.
7
0
–
0
.
7
3
(
F
a
h
e
y
e
t
a
l
.
1
9
9
5
)
S
c
r
e
e
n
i
n
g
f
r
e
q
u
e
n
c
y
/
%
c
o
m
p
l
i
a
n
c
e
a
3
y
e
a
r
s
/
6
0
%
1
y
e
a
r
/
4
8
%
5
y
e
a
r
s
/
7
2
%
S
c
h
a
f
f
e
r
e
t
a
l
.
(
2
0
0
0
)
,
C
o
c
h
a
n
d
-
P
r
i
o
l
l
e
t
e
t
a
l
.
(
2
0
0
4
)
P
e
r
c
e
n
t
a
g
e
o
f
p
a
t
i
e
n
t
s
w
i
t
h
d
e
t
e
c
t
e
d
C
I
N
1
t
r
e
a
t
e
d
/
e
f
ﬁ
c
a
c
y
o
f
t
r
e
a
t
m
e
n
t
5
0
/
9
5
%
N
A
N
A
S
a
n
d
e
r
s
a
n
d
T
a
i
r
a
(
2
0
0
3
,
B
e
r
g
e
r
o
n
e
t
a
l
.
(
2
0
0
6
)
,
e
x
p
e
r
t
o
p
i
n
i
o
n
P
e
r
c
e
n
t
a
g
e
o
f
p
a
t
i
e
n
t
s
w
i
t
h
d
e
t
e
c
t
e
d
C
I
N
2
/
3
t
r
e
a
t
e
d
/
e
f
ﬁ
c
a
c
y
o
f
t
r
e
a
t
m
e
n
t
1
0
0
/
9
5
%
N
A
N
A
E
x
p
e
r
t
o
p
i
n
i
o
n
U
n
i
t
c
o
s
t
s
(
l
i
m
i
t
e
d
s
o
c
i
e
t
a
l
p
e
r
s
p
e
c
t
i
v
e
,
i
.
e
.
a
l
l
d
i
r
e
c
t
h
e
a
l
t
h
c
a
r
e
c
o
s
t
s
)
S
c
r
e
e
n
i
n
g
,
n
e
g
a
t
i
v
e
/
p
o
s
i
t
i
v
e
p
a
p
t
e
s
t
€
4
8
.
5
7
€
3
8
.
8
6
€
5
8
.
2
8
B
e
r
g
e
r
o
n
e
t
a
l
.
(
2
0
0
6
)
S
c
r
e
e
n
i
n
g
?
p
o
s
i
t
i
v
e
p
a
p
€
4
9
.
7
8
€
3
9
.
8
2
€
5
9
.
7
3
B
e
r
g
e
r
o
n
e
t
a
l
.
(
2
0
0
6
)
T
r
e
a
t
m
e
n
t
o
f
d
e
t
e
c
t
e
d
C
I
N
1
,
y
e
a
r
1
€
2
7
0
.
5
2
€
2
1
6
.
4
2
€
3
2
4
.
6
2
B
e
r
g
e
r
o
n
e
t
a
l
.
(
2
0
0
6
)
T
r
e
a
t
m
e
n
t
o
f
d
e
t
e
c
t
e
d
C
I
N
2
/
3
,
y
e
a
r
1
€
1
,
0
6
4
.
0
8
€
8
5
1
.
2
6
€
1
,
2
7
6
.
9
0
B
e
r
g
e
r
o
n
e
t
a
l
.
(
2
0
0
6
)
T
r
e
a
t
m
e
n
t
o
f
d
e
t
e
c
t
e
d
C
I
N
1
,
y
e
a
r
2
€
4
8
.
5
7
€
3
8
.
8
6
€
5
8
.
2
8
B
e
r
g
e
r
o
n
e
t
a
l
.
(
2
0
0
6
)
T
r
e
a
t
m
e
n
t
o
f
d
e
t
e
c
t
e
d
C
I
N
2
/
3
,
y
e
a
r
2
€
9
7
.
1
4
€
7
7
.
7
1
€
1
1
6
.
5
7
B
e
r
g
e
r
o
n
e
t
a
l
.
(
2
0
0
6
)
C
a
n
c
e
r
t
r
e
a
t
m
e
n
t
s
t
a
g
e
I
-
I
V
€
1
3
,
5
0
8
.
5
1
€
1
0
,
8
0
6
.
8
1
€
1
6
,
2
1
0
.
2
1
A
r
v
e
u
x
e
t
a
l
.
(
2
0
0
7
)
Cost-effectiveness of cervical cancer vaccination 155
123T
a
b
l
e
1
c
o
n
t
i
n
u
e
d
P
a
r
a
m
e
t
e
r
B
a
s
e
c
a
s
e
v
a
l
u
e
U
n
i
v
a
r
i
a
t
e
s
e
n
s
i
t
i
v
i
t
y
a
n
a
l
y
s
i
s
R
e
f
e
r
e
n
c
e
L
o
w
e
r
U
p
p
e
r
V
a
c
c
i
n
e
c
o
s
t
p
e
r
d
o
s
e
€
1
3
3
.
8
2
€
1
0
7
.
0
6
€
1
6
0
.
5
8
D
i
s
u
t
i
l
i
t
y
s
c
o
r
e
s
b
C
I
N
1
d
e
t
e
c
t
e
d
0
.
0
1
2
8
0
.
0
1
0
0
.
0
1
5
C
I
N
2
/
3
d
e
t
e
c
t
e
d
0
.
0
0
9
3
7
6
0
.
0
0
8
0
.
0
1
1
C
a
n
c
e
r
0
.
2
7
3
0
.
2
1
8
0
.
3
2
8
G
o
l
d
e
t
a
l
.
(
1
9
9
8
)
,
I
n
s
t
i
t
u
t
e
o
f
M
e
d
i
c
i
n
e
(
2
0
0
0
)
,
G
o
l
d
i
e
e
t
a
l
.
(
2
0
0
4
)
,
M
y
e
r
s
e
t
a
l
.
(
2
0
0
4
)
,
I
n
s
i
n
g
a
e
t
a
l
.
(
2
0
0
5
)
C
a
n
c
e
r
c
u
r
e
d
0
.
0
6
2
0
.
0
5
0
0
.
0
7
4
V
a
c
c
i
n
e
e
f
ﬁ
c
a
c
y
P
r
e
-
H
P
V
e
x
p
o
s
u
r
e
(
H
P
V
N
a
ı
¨
v
e
)
C
I
N
1
?
(
H
P
V
1
6
/
1
8
)
9
8
.
0
%
8
0
%
1
0
0
%
P
a
a
v
o
n
e
n
e
t
a
l
.
(
2
0
0
9
)
,
R
o
m
a
n
o
w
s
k
i
e
t
a
l
.
(
2
0
0
9
)
C
I
N
2
?
c
r
o
s
s
-
p
r
o
t
e
c
t
i
o
n
a
g
a
i
n
s
t
o
t
h
e
r
h
i
g
h
-
r
i
s
k
H
P
V
(
c
r
o
s
s
-
p
r
o
t
e
c
t
i
o
n
)
6
8
.
4
%
4
0
%
8
4
%
S
k
i
n
n
e
r
e
t
a
l
.
(
2
0
0
9
)
,
S
z
a
r
e
w
s
k
i
(
2
0
1
0
)
C
I
N
1
(
c
r
o
s
s
-
p
r
o
t
e
c
t
i
o
n
)
4
7
.
7
%
2
9
%
6
2
%
T
j
a
l
m
a
e
t
a
l
.
(
2
0
0
9
)
P
o
s
t
-
H
P
V
e
x
p
o
s
u
r
e
(
D
N
A
-
r
e
g
a
r
d
l
e
s
s
o
f
t
h
e
s
e
r
o
-
s
t
a
t
u
s
)
C
I
N
1
?
(
H
P
V
1
6
/
1
8
)
8
9
.
1
%
N
A
N
A
W
h
e
e
l
e
r
a
n
d
H
P
V
P
a
t
r
i
c
i
a
S
t
u
d
y
G
r
o
u
p
(
2
0
1
0
)
C
I
N
2
?
(
c
r
o
s
s
-
p
r
o
t
e
c
t
i
o
n
)
4
7
.
3
%
N
A
N
A
C
I
N
1
(
c
r
o
s
s
-
p
r
o
t
e
c
t
i
o
n
)
3
3
.
5
%
N
A
N
A
W
a
n
i
n
g
a
n
d
b
o
o
s
t
e
r
c
N
o
n
e
1
5
y
e
a
r
1
b
o
o
s
t
2
0
y
e
a
r
1
b
o
o
s
t
G
e
n
e
r
a
l
v
a
r
i
a
b
l
e
s
D
i
s
c
o
u
n
t
r
a
t
e
c
o
s
t
s
/
b
e
n
e
ﬁ
t
s
3
/
1
.
5
%
0
/
0
%
5
/
5
%
A
s
s
u
m
p
t
i
o
n
H
P
V
1
6
/
1
8
i
n
p
o
p
u
l
a
t
i
o
n
(
a
g
e
-
d
e
p
e
n
d
e
n
t
)
3
.
6
–
1
2
.
2
8
%
2
0
%
l
e
s
s
t
h
a
n
b
a
s
e
c
a
s
e
2
0
%
m
o
r
e
t
h
a
n
b
a
s
e
c
a
s
e
H
P
V
1
6
/
1
8
i
n
I
C
C
7
1
%
5
6
.
8
%
8
5
.
2
%
C
l
i
f
f
o
r
d
e
t
a
l
.
(
2
0
0
3
)
a
S
c
r
e
e
n
i
n
g
p
r
a
c
t
i
c
e
:
a
l
l
w
o
m
e
n
s
c
r
e
e
n
e
d
e
v
e
r
y
3
y
e
a
r
s
b
e
t
w
e
e
n
t
h
e
a
g
e
s
o
f
2
5
a
n
d
6
0
y
e
a
r
s
b
H
e
a
l
t
h
s
t
a
t
e
s
N
o
H
P
V
,
H
P
V
,
C
I
N
1
a
n
d
C
I
N
2
/
3
h
a
v
e
u
t
i
l
i
t
y
=
1
(
i
.
e
.
n
o
d
i
s
u
t
i
l
i
t
y
)
;
h
e
a
l
t
h
s
t
a
t
e
s
d
e
a
t
h
a
n
d
d
e
a
t
h
f
r
o
m
c
e
r
v
i
c
a
l
c
a
n
c
e
r
h
a
v
e
u
t
i
l
i
t
y
=
0
c
W
a
n
i
n
g
a
s
s
u
m
e
d
t
o
b
e
g
i
n
5
y
e
a
r
s
b
e
f
o
r
e
r
e
a
c
h
i
n
g
0
%
e
f
ﬁ
c
a
c
y
,
b
o
o
s
t
e
r
a
s
s
u
m
e
d
t
o
p
r
o
v
i
d
e
l
i
f
e
l
o
n
g
p
r
o
t
e
c
t
i
o
n
t
h
e
r
e
a
f
t
e
r
C
I
N
c
e
r
v
i
c
a
l
i
n
t
r
a
e
p
i
t
h
e
l
i
a
l
n
e
o
p
l
a
s
i
a
;
H
P
V
h
u
m
a
n
p
a
p
i
l
l
o
m
a
v
i
r
u
s
;
I
C
C
i
n
v
a
s
i
v
e
c
e
r
v
i
c
a
l
c
a
n
c
e
r
;
N
A
n
o
t
i
n
c
l
u
d
e
d
i
n
u
n
i
v
a
r
i
a
t
e
s
e
n
s
i
t
i
v
i
t
y
a
n
a
l
y
s
i
s
156 N. Demarteau et al.
123to death and death from cervical cancer by deﬁnition. The
disutility values, estimated over a 1 year period, for the
other health states (detected CIN, cervical cancer and cured
cervical cancer) were taken from published sources (Gold
et al. 1998; Institute of Medicine 2000; Goldie et al. 2004;
Myers et al. 2004; Insinga et al. 2005) and based both on
the disutility experienced by the women and the duration of
the disease in order to adjust to the 1 year cycle. They are
listed in Table 1.
Vaccine efﬁcacy
Vaccine efﬁcacy data were taken from clinical trials and
include cross protection (vaccine efﬁcacy against non
vaccine HPV types i.e., non HPV 16 and 18) assuming a
reduction only in new infections (from no HPV to HPV)
and no effect on existing infections or lesions. Vaccine
efﬁcacy was differentiated for females in pre- (HPV naı ¨ve)
versus post-HPV exposure condition (Total Vaccinated
Cohort DNA negative irrespective of HPV sero-status data
(TVC DNA neg)). A cut-off date of 17 years of age was
selected to differentiate between pre- and post exposure
based on the average age of sexual debut in France
(Wellings et al. 2006). That info was combined with data
on the proportion of HPV due to these HPV types (WHO/
ICO 2010) (and data on cross-protection (protection
beyond HPV 16/18) to calculate the overall reduction in
cervical cancer and CIN cases, corrected for the lower
proportion of CIN cases caused by oncogenic HPV
(Debicki et al. 2008), The values used are listed in Table 1.
Discount rate
In the base case scenario, costs were discounted at a rate of
3% and outcomes at a rate of 1.5% (Table 1). The discount
rate of 1.5% for outcomes was selected for ethical reasons,
as a higher discount rate would undervalue clinical beneﬁts
felt by future generations and this was considered unac-
ceptable by the authors. This parameter was tested in
sensitivity analysis (Table 1). Differential discount for cost
and effect is also applicable in other countries such as
Belgium and the Netherlands (ISPOR 2010).
Model calibration and validation
The model was calibrated to the cancer incidence rates
reported in the French national registry (Exbrayat 2002), by
adjusting the transition probability for persistent CIN 2/3 to
cervical cancer. This transition probability was selected for
calibration as no data are available about this transition
probability and therefore had to be assumed.
The model was tested against the criteria published by
the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) (Weinstein et al. 2003).
External validity was tested by entering the input data for
models previously published by Goldie et al. (1999, 2004;
Kohli et al. 2007), and Kulasingam and Myers (2003), and
comparing the results.
Analysis
Thebasecaseanalysiscomparedthecostsandoutcomesofa
girlscohortreceivingscreeningaccordingtocurrentpractice
in France with those of a cohort receiving screening plus
vaccination at age 12 years. We calculated the incremental
cost-effectiveness ratio (ICER), expressed as the incremen-
tal cost per QALY gained or per life-year gained for the
vaccinatedcohortcomparedwiththenon-vaccinatedcohort.
Speciﬁc scenarios such as age at vaccination and the
effects of implementing a catch-up programme with vac-
cination of additional cohorts up to 25 years of age were
also investigated assuming constant efﬁcacy across ages.
Sensitivity analysis
Univariatedeterministicsensitivityanalyseswereconducted
to assess the effect of uncertainty around the input values on
themodeloutput.ThevaluesusedarelistedinTable 1.Most
parameters were varied by ±20% from the base case values,
with the exception of the vaccine cross-protection rate
(minimum of 0%), the vaccine efﬁcacy rates (maximum of
100%), and the screening frequency (±2 years). As the
vaccine coverage rate does not affect the ICER (for any
change in coverage, the changes in costs and outcomes are
proportional so the ICER does not change), this parameter
was not varied (Sua ´rez et al. 2008).
A probabilistic sensitivity analysis was performed using
@Risk version 5.0 (Palisade Corporation, Ithaca, New
York, USA). Distributions were assigned to transition
probabilities, costs, utility and vaccine-related data using
normal distributions (limited between 0 and 1 for transition
probabilities) when conﬁdence intervals were available,
and beta distributions ranging from 20% below the base
case value to 20% above the base case value otherwise. A
total of 5,000 replicates were obtained using these distri-
butions and used to derive a conﬁdence interval (CI)
around the ICER and to conduct a multivariate stepwise
linear regression analysis. This analysis identiﬁes the
variables in the probabilistic analysis that have the largest
impact on the ICER result. The regression coefﬁcients
measured were normalised and a value of 0 corresponds to
no signiﬁcant relationship between the input variable and
the output result. A value of ?1o r-1 indicates that a
change of ?1o r-1 standard deviation in the input variable
results in an equivalent change in the output result (Sua ´rez
et al. 2008).
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Model validation
As shown in Fig. 1, the model results closely matched the
incidence and mortality data for invasive cervical cancer
reported by the French national cancer registry (Exbrayat
2002) for women aged 60–65 years or less, although the
model tends to underestimate cancer incidence and mor-
tality at older ages.
It fully met all the ISPOR criteria except that the model
does not account for the time spent in one health state
before transition to another state. The model was also able
to replicate the results of a previously published model
when run with the input data used for this model, further
supporting our model’s validity.
Single cohort analysis
Table 2 shows the base case estimated costs, outcomes and
ICER for vaccination of a single cohort of 100,000 girls at
age 12 years plus current screening compared with current
screening alone. Addition of vaccination at age 12 years to
current screening would avoid 749 cases of cervical cancer
and 244 deaths from cervical cancer and would gain 5,819
life-years and 6,723 QALYs, compared with screening
alone. The estimated discounted ICER was €9,706/QALY.
Discounting had a major effect on the results. Without
discounting, the estimated ICER would be €309/QALY
Table 2.
Effect of age at vaccination
Figure 2 shows the effect of age at vaccination on the
ICER and on the numbers of cervical cancer cases avoided
and life-years saved. It can be clearly seen that the esti-
mated beneﬁts of adding vaccination to screening were
greatest with vaccination at younger ages (before sexual
debut), although substantial beneﬁts still accrue even for
vaccination at later ages. Approximately 85% of deaths
from invasive cervical cancer would be avoided by vacci-
nation at age 12 years, and for vaccination at age 40 years
the corresponding value would be approximately 34%. The
estimated ICER was also most favourable when vaccina-
tion was carried out at age 12, and this was true regardless
of discounting (Fig. 2). At a cost-effectiveness threshold of
50,000€/QALY, vaccination would remain cost effective
up to the age of 40 years.
Multiple cohort analysis
Theeffectsofacatch-upvaccinationprogrammeforwomen
up to the age of 25 years were also explored in a multiple
cohort analysis. For a one-year vaccination campaign cov-
ering girls and women aged 12–25 years, the ICER for
addingvaccinationtoscreeningwasestimatedat€13,079per
QALY.Fora20-yearcampaign,includingallnewcohortsof
12-year-old girls over the total campaign, the ICER was
estimated at €10,465 across the entire multiple cohort.
Sensitivity analysis
Figure 3 shows the results of the univariate sensitivity
analysis as a Tornado plot, with each parameter being
varied according to the limits shown in Table 1. The dis-
count rate was the most inﬂuential parameter. Most other
parameters had only a small effect on the ICER.
The 95% conﬁdence intervals for the ICER, determined
from the probabilistic sensitivity analysis, ranged from
€2,376/QALY to €33,978/QALY. Figure 4 shows the
regression coefﬁcient for all signiﬁcant results determined
from the multivariate stepwise analyses, displaying the
level of impact of each on the discounted ICER. These
results showed that the most inﬂuential parameters were
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the French national cancer registry (Exbrayat 2002)( diamonds)
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123those related to the disease history: progression and
regression from HPV, CIN1 and CIN2/3.
Discussion
Healthcare authorities and policymakers need to evaluate
the economic impact of healthcare interventions to decide
on the allocation of scarce resources. But not all national or
regional authorities have access to detailed information on
HPV epidemiology, age-speciﬁc sexual behaviour or the
patterns of cervical cancer screening and treatment, and this
lack of data may make it difﬁcult to investigate the potential
impact of cervical cancer vaccines. The model presented
herehasdespiteseverallimitations,importantadvantages.It
requiresalimitedamountofinputdatathatshouldbereadily
available in most countries and regions. It represents a gen-
erally applicable tool that can help answer key economic
questions on cervical cancer vaccination, such as the effects
of age at vaccination, catch-up programmes, or different
screening practices. These evaluations may be useful when
assessing the potential public health impact of different
policy options.
The model showed good agreement with cervical cancer
incidence and mortality data reported by the French
national cancer registry for women aged\60–65 years, but
underestimated both parameters for women in older age
groups (Fig. 1). This may be because the registry data
reﬂect current incidence and mortality based on past
screening practice, whereas the model projects current
screening practice into the future. Improvements in
screening practice would be expected to reduce the future
incidence of cervical cancer, but this may not yet be fully
reﬂected in current observed data in older age groups who
would have been screened according to past practice. We
were able to replicate the ﬁndings of previously published
models when our model was run with their input data, and
the present model has been shown to produce results
similar to those from a more detailed cohort model when
tested with data from four countries (Canada, Italy, Taiwan
and UK) (Debicki et al. 2008). The ﬁndings therefore
indicate that the current model is robust and they give
conﬁdence in the cost-effectiveness results of HPV vacci-
nation plus screening compared with screening alone.
Themodelresultspresentedhereshowthattheadditionof
vaccination with a bivalent HPV vaccine to current cervical
screening practice in France would substantially reduce the
incidence of and mortality from cervical cancer, at an esti-
mated ICER of €9,706/QALY from a direct healthcare cost
perspective. The greatest beneﬁts and most favourable
Table 2 Cost-effectiveness in a
single cohort of 100,000 girls
vaccinated at age 12 years, base
case
ICER Incremental cost-
effectiveness ratio; QALY
Quality-adjusted life-year
Screening
only (A)
Screening ?
vaccination (B)
Difference
(B - A)
ICER
Undiscounted
Cost, € 85,157,804€ 87,237,683€ 2,079,879
Life-years 7,154,155€ 7,159,974€ 5,819
Cervical cancer cases 876 127 -749
Cervical cancer deaths 285 41 -244
QALYs 7,153,096€ 7,159,819 € 6,723 309
Discounted
Cost, € 30,034,919€ 58,782,797€ 28,747,878
QALYs 4,387,672€ 4,390,634€ 2,962 9,706
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123cost-effectiveness would be obtained with vaccination at
younger ages (before sexual debut), but substantial beneﬁts
would still be obtained with vaccination at older ages. For
example, vaccination at age 40 years would still prevent an
estimated 35% of cases of invasive cervical cancer, com-
pared with screening alone. These beneﬁts account for a
decrease in vaccine efﬁcacy in previously infected women.
As expected for a preventive intervention where beneﬁt
occursmanyyearsaftertheintervention,theresultsaremost
sensitivetothediscountrateandtheparametersrelatedtothe
natural history of the disease.
Ourmodelhasanumberoflimitations.Itisnotadynamic
transmission model and therefore does not take into account
the beneﬁts of herd protection. It would thus underestimate
the true beneﬁt of vaccination in that respect. Other pub-
lishedmodelsofcervicalcancerhaveconsideredthisaspect,
but these models require much more detailed data than is
readily available in France and more computational power.
Also, given a succinct model was used, a trade off had to be
made between the complexity of the scenarios investigated
andtheirfeasibility.Forinstanceourmodeldoesnotinclude
HPVtypespeciﬁchealthstates,thereforecomplexscreening
pattern such as including HPV DNA testing (Rogoza et al.
2008) or the effect of HPV type speciﬁc lesions could not be
investigated. Furthermore, we did not account for type
replacement or speciﬁcally investigate the effect of vacci-
nation on co-infection. One of the uncertainties about HPV
vaccination is indeed whether other HPV types will replace
theHPVtypestargetedbythevaccines.Todatethisquestion
cannot be answered, but available evidence suggests that
niche competition is unlikely (Stanley et al. 2006). On the
otherhandbyincludingonlyoneHPVhealthstatewedonot
facetheproblemofincreasingsusceptibilitytononprotected
HPV types with the vaccine as encountered with other
models (Goldie et al. 2004). Finally, our analysis focuses on
cost-effectiveness analysis. This, however, does not account
forissueofbudgetimpactandthereforeaffordabilitythatcan
be assessed by the model but is at the end a decision to be
taken by the local health authorities.
A recently published study also investigated the cost-
effectiveness of HPV vaccination in France, using a
quadrivalent HPV vaccine (Bergeron et al. 2008). This
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Base case Fig. 3 One-way sensitivity
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123study was an adaptation of the model previously published
by Kulasingam and Myers (2003), and compared screening
plus vaccination at age 14 years with screening alone. The
ICER for the addition of vaccination to screening was
€13,809/QALY when considering all direct healthcare
costs (Bergeron et al. 2008). This is somewhat higher than
our ﬁnding of €9,706/QALY for the bivalent vaccine,
although it should be noted that no study undertook a direct
head-to-head comparison of the two products and the
results may therefore not be directly comparable.
This paper describes a succinct cohort model that can be
used to investigate key economic issues in HPV vaccination
for the prevention of cervical cancer. The model results
agreedwellwithobserveddatainFrance,asshownhere,and
indicate that HPV vaccination would be a cost-effective
policy option. As the model uses data that are readily
available in most countries and regions, it should be gener-
ally applicable to the evaluation of the cost effectiveness of
HPV vaccination in a variety of settings.
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